Close Menu

NEW YORK (360Dx) – Ortho Clinical Diagnostics said today that it has received US Food and Drug Administration approval to market its Sera blood-grouping reagents with its ID-Micro Typing System gel card technology for extended phenotype testing.

Ortho's Sera reagents are used to determine the status of a designated antigen on human red blood cells. The firm noted that the reagents provide labs with a menu of antisera for phenotyping that's available in a gel testing format, and that covers more than 99 percent of the most commonly tested blood-group antigens.  

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.